Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. We investigated the...
Main Authors: | Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-09-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20927383/?tool=EBI |
Similar Items
-
Proteasome inhibition and its therapeutic potential in multiple myeloma
by: Ajai Chari, et al.
Published: (2010-09-01) -
Quantitative dynamics of phosphoproteome: the devil is in the details.
by: Salek, M, et al.
Published: (2012) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01) -
Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics
by: He Qiu-Yan, et al.
Published: (2011-06-01) -
Phosphoproteome profiling of mouse liver during normal aging
by: Jiang-Feng Liu, et al.
Published: (2022-08-01)